MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


TOP NEWS: Croda International cuts outlook as profit slumps 18%

ALN

Croda International PLC on Tuesday reported a weaker first-half performance, although it said the business is on track for future growth with investments delivering greater efficiencies and capacity.

The Yorkshire, England-based chemical company said in the six months that ended June 30, pretax profit fell 18% to £106.1 million from £128.7 million the previous year.

Revenue declined by 7.4% to £815.9 million from £880.9 million, while cost of sales fell 10% to £448.7 million from £498.4 million.

Croda maintained an interim dividend of 47.0 pence per share.

Net debt increased by 45% to £507.9 million from £349.3 million.

‘We are encouraged by first half performance in Consumer Care, key strategic Pharma platforms and Industrial Specialties, with improving operating margins driven by higher sales volumes, price discipline and robust cost control.

‘However, with a weaker than anticipated performance in Life Sciences due to continued destocking in Crop Protection and consumer health, and no signs of an immediate recovery in Crop Protection,’ Croda said.

To ensure future growth, the company has realigned its portfolio and invested in research and development to capture the benefits of trends toward sustainable ingredients and demand for high levels of innovation in biologics.

In addition, plans are in place to invest £175 million from 2021 to 2025 to add multi-purpose manufacturing capacity. So far £120 million has been invested as part of the programme with the US and UK governments together providing an additional £75 million.

Croda said: ‘A new organisational structure has been in place since the start of 2024 which makes Consumer Care and Life Sciences fully accountable for strategy and performance. The new organisation has clarified accountabilities, is ensuring we deliver more quickly and effectively for our customers and has simplified our structure for employees.’

The new, more efficient structure, is set to deliver annual cost savings of £9 million from 2025.

In light of the weak half-year results, guidance for the full year was lowered by Croda, with management now expecting to generate full-year adjusted pretax profit between £260 million and £280 million at constant currency, down from £260 million to £300 million. At the lower end, this would reflect a 15% decline from £308.8 million in 2023.

Croda shares were down 3.7% to 3,953.00 pence each in London on Tuesday morning.

Copyright 2024 Alliance News Ltd. All Rights Reserved.